TRANSGENE news, videos and press releases - Page 3
For more news please use our advanced search feature.
TRANSGENE - More news...
TRANSGENE - More news...
- Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
- Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
- Transgene Reports Business Update and Q3 2021 Financial Position
- Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
- Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
- Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
- Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
- Transgene Announces Upcoming Investor Meetings
- Transgene Participates in New Cancer Research Consortium
- Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2021
- First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
- Transgene Announces the Success of Its Capital Increase via a Private Placement
- Transgene Launches a Capital Increase via a Private Placement
- Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
- Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
- Transgene: Combined General Meeting of May 26, 2021
- Transgene Reports Business Update and End Q1 2021 Financial Position
- Transgene Announces Upcoming Investor Meetings
- Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
- Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
- Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
- Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
- Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
- First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
- Transgene Appoints Gaëlle Stadtler as Director of Human Resources
- Report on the Transgene Liquidity Contract with Natixis Oddo BHF SCA as of December 31, 2020
- Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors